Pacific Biosciences Of California (PACB) Net Cash Flow Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 129.29% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -48.90% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -65.12% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn | -31.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.18% |
| Dec 31, 2025 | -30.41% |
| Sep 30, 2025 | 31.55% |
| Jun 30, 2025 | 67.60% |
| Mar 31, 2025 | 28.03% |
| Dec 31, 2024 | -38.20% |
| Jun 30, 2024 | 26.98% |
| Mar 31, 2024 | -28.49% |
| Dec 31, 2023 | -160.52% |
| Sep 30, 2023 | 90.06% |
| Jun 30, 2023 | -77.31% |
| Mar 31, 2023 | -9.85% |
| Dec 31, 2022 | 99.79% |
| Sep 30, 2022 | -61.41% |
| Jun 30, 2022 | -143.42% |
| Mar 31, 2022 | -53.83% |
| Dec 31, 2021 | 56.60% |
| Jun 30, 2021 | -482.21% |
| Mar 31, 2021 | 356.37% |
| Dec 31, 2020 | 50.25% |